These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15702040)

  • 21. Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.
    Pace D; Khatami A; Attard-Montalto S; Voysey M; Finn A; Faust SN; Heath PT; Borrow R; Snape MD; Pollard AJ
    Vaccine; 2016 Dec; 34(50):6350-6357. PubMed ID: 28029540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.
    Richmond P; Borrow R; Findlow J; Martin S; Thornton C; Cartwright K; Miller E
    Infect Immun; 2001 Apr; 69(4):2378-82. PubMed ID: 11254596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
    Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
    Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
    Tejedor JC; Brzostek J; Konior R; Grunert D; Kolhe D; Baine Y; Van Der Wielen M
    Clin Vaccine Immunol; 2016 Jul; 23(7):555-63. PubMed ID: 27145999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.
    Auckland C; Gray S; Borrow R; Andrews N; Goldblatt D; Ramsay M; Miller E
    J Infect Dis; 2006 Dec; 194(12):1745-52. PubMed ID: 17109348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
    Pace D; Khatami A; McKenna J; Campbell D; Attard-Montalto S; Birks J; Voysey M; White C; Finn A; Macloed E; Faust SN; Kent AL; Heath PT; Borrow R; Snape MD; Pollard AJ
    BMJ; 2015 Apr; 350():h1554. PubMed ID: 25832102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
    Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
    Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction.
    Ishola DA; Borrow R; Findlow H; Findlow J; Trotter C; Ramsay ME
    Clin Vaccine Immunol; 2012 Aug; 19(8):1126-30. PubMed ID: 22647271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
    de Whalley PC; Snape MD; Plested E; Thompson B; Nuthall E; Omar O; Borrow R; Pollard AJ
    Arch Dis Child; 2013 Sep; 98(9):686-91. PubMed ID: 23853000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis for protection rate and antibody levels of epidemic cerebrospinal meningitis among children aged between 3-23 months in Liuzhou, in 2012].
    Cui XL; Wu X; Li MQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1079-1083. PubMed ID: 28057112
    [No Abstract]   [Full Text] [Related]  

  • 32. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers.
    Vesikari T; Borrow R; Da Costa X; Thomas S; Eymin C; Boisnard F; Lockhart S
    Vaccine; 2018 Dec; 36(52):8019-8027. PubMed ID: 30471953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparison on the levels of human serum antibody against Neisseria meningitidis serogroup C measured using serum bactericidal assay and ELISA].
    Zhu BQ; Xu L; Zhou HJ; Shao ZJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 May; 33(5):521-4. PubMed ID: 22883183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination.
    Pérez-Breva L; Abad-Torreblanca R; Martínez-Beneito MÁ; Puig-Barberà J; Alemán-Sánchez S; Morant-Talamante N; Sastre-Cantón M; Vázquez-Moreno JA; Díez-Domingo J
    Vaccine; 2017 May; 35(22):2949-2954. PubMed ID: 28438407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of saliva to monitor meningococcal vaccine responses: proposing a threshold in saliva as surrogate of protection.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    BMC Med Res Methodol; 2019 Jan; 19(1):1. PubMed ID: 30611213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months.
    Díez-Domingo J; Cantarino MV; Torrentí JM; Sansano MI; Rosich AJ; Merino AH; de Miguel AG; González JB; Marcos MD;
    Pediatr Infect Dis J; 2010 Feb; 29(2):148-52. PubMed ID: 19927040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody.
    Perrett KP; Jin C; Clutterbuck E; John TM; Winter AP; Kibwana E; Yu LM; Curtis N; Pollard AJ
    J Immunol; 2012 Sep; 189(5):2673-81. PubMed ID: 22855707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine.
    Blanchard-Rohner G; Watt H; Kelly DF; Yu LM; Snape MD; Pollard AJ
    Vaccine; 2012 Jun; 30(28):4153-9. PubMed ID: 22554466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil.
    Andrade AL; Minamisava R; Tomich LM; Lemos AP; Gorla MC; de Cunto Brandileone MC; Domingues CMS; de Moraes C; Policena G; Bierrenbach AL;
    Vaccine; 2017 Apr; 35(16):2025-2033. PubMed ID: 28318769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.